PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
771
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, 21 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from BlackRock, Inc. on 16 May 2018.

BlackRock, Inc. (taking into account the holdings of its subsidiary undertakings) notified Ablynx that it has downward crossed the 3% threshold of total voting rights of Ablynx since 14 May 2018.

The notification contains the following information:

  • Reason for the notification :
    • acquisition or disposal of voting securities or voting rights
    • downward crossing of the lowest threshold
  • Notification by : a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
Name Address (for legal entities)
BlackRock, Inc. 55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock Advisors (UK) Limited 12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC 100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A.
BlackRock Asset Management Deutschland AG Max-Joseph-Straße 6, Munich, 80333, Germany
BlackRock Fund Advisors 400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association 400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Investment Management (UK) Limited 12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC 1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd. 1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan
  • Transaction date : 14 May 2018
  • Threshold that is crossed : 3% (of the total holding)
  • Denominator : 75,406,551 (status 14 May 2018)
  • Details: no details required when crossing the lowest threshold
  • Chain of controlled undertakings through which the holding is effectively being held : Please see the full chain of control in the Transparency Notification.
  • Additional information: The disclosure obligation arose due total holding in voting rights for BlackRock, Inc. going below 3%.

A full version of the transparency notification is available on Ablynx website, under the section Investors .

The Articles of the Association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

On 29 January 2018, Sanofi made an offer to acquire all of Ablynx's outstanding ordinary shares (including shares represented by American Depository Shares (ADSs), warrants and convertible bonds (collectively with the outstanding ordinary shares, the " Securities ")) at a price of €45 per share, which represents an aggregate equity value of approximately €3.9 billion. The proposed transaction was unanimously approved by both the Sanofi and Ablynx Board of Directors. The offer is comprised of two separate but concurrent tender offers: (i) a tender offer under the laws of Belgium for all of the outstanding shares, warrants and convertible bonds of Ablynx (the " Belgian Offer ") and (ii) a tender offer under the laws of the U.S. for all of the outstanding shares held by U.S. holders and ADSs held by holders, wherever located (the " U.S. Offer " and together with the Belgian Offer, the " Offers "). The initial acceptance period of the tender offers commenced on 4 April 2018 and expired at 5:00 p.m. ET / 11:00 p.m. CET on 4 May 2018.

Sanofi confirmed on 14 May 2018 that, as of the expiration of the initial acceptance period, a total of 71,972,994 shares (including 7,446,312 shares represented by ADSs), 2,594,841 warrants and 975 convertible bonds had been validly tendered into the Offers and not withdrawn. Sanofi will own 95.60% of the outstanding shares of Ablynx on the settlement date of the Offers, of which more than 90% were acquired through the Offers. Sanofi further confirmed that the Minimum Tender Condition and the other conditions to the Offers have been satisfied.

Sanofi has decided to proceed with a squeeze-out of those Securities not tendered to the Offers in accordance with applicable Belgian and U.S. law. In this regard, Sanofi will reopen the Offers and commence the squeeze-out period on May 22, 2018, to acquire those Securities not previously tendered into the Offers. The squeeze-out period will expire on June 12, 2018 at 5.00 p.m. New York City time / 11.00 p.m. CEST time.

Please see below for more information on the tender offers.

For more information, please contact

Ablynx Dr Edwin Moses CEO t:   +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e:  edwin.moses@ablynx.com

Lies Vanneste Director Investor Relations t:   +32 (0)9 262 01 37 m: +32 (0)498 05 35 79 e:  lies.vanneste@ablynx.com

Ablynx media relations: Consilium Strategic Communications Mary-Jane Elliott, Philippa Gardner, Sukaina Virji t:  +44 (0)20 3709 5700 e:  ablynx@consilium-comms.com

Joele Frank, Wilkinson Brimmer Katcher Dan Katcher or Joseph Sala t: +1 212 355-4449

Additional information on the Belgian Offer An electronic version of the prospectus (including the forms) can be found on the websites of the Receiving & Paying Agents (for BNP Paribas Fortis NV/SA, https://www.bnpparibasfortis.be/epargneretplacer (French and English) and https://www.bnpparibasfortis.be/sparenenbeleggen (Dutch and English); for KBC Securities NV/SA in cooperation with KBC Bank NV/SA, https://www.kbcsecurities.com/prospectus-docu...s-overview , https://www.kbc.be , https://www.cbc.be and https://www.bolero.be ), Sanofi ( https://www.sanofi.com/en/investors/tender-offers-ablynx and https://www.sanofi.com/fr/investisseurs/offres-ablynx ) and Ablynx ( http://www.ablynx.com/investors/sanofi-takeover-bid/ ). The Prospectus can also be obtained in hard copy free of charge (i) at the counters of the Receiving & Paying Agents or (ii) by contacting the Receiving & Paying Agents at +32 (0)2 433 41 13 (BNP Paribas Fortis NV/SA), +32 (0)78 15 21 53 (KBC Bank NV/SA, Dutch & English), +32 (0) 800 92 020 (CBC Banque NV/SA, French & English) or +32 32 83 29 81 (Bolero by KBC Securities NV/SA, Dutch, French & English). The Prospectus is available in English and Dutch. The summary of the prospectus is also available in French.

The Response Memorandum is annexed to the prospectus. The Response Memorandum can also be obtained in hard copy free of charge at the registered office of Ablynx (Technologiepark 21, 9052 Zwijnaarde (Belgium)). The Response Memorandum is available in English and Dutch.

Additional Information on the U.S. Offer This communication is for informational purposes only and is neither a recommendation, an offer to purchase nor a solicitation of an offer to sell any Securities of Ablynx. Sanofi has filed a Tender Offer Statement on Schedule TO with the SEC and Ablynx has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC. Holders of Securities are urged to carefully review the documents that were filed by Sanofi and Ablynx with the SEC because these documents will contain important information, including the terms and conditions of the tender offer.

The offer to purchase, the related ADS letter of transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement are available to all holders of Securities of Ablynx at no expense to them. These documents are available for free at the SEC's website at www.sec.gov. Additional copies may be obtained for free by contacting Sanofi at ir@Sanofi.com or on Sanofi's website at https://en.Sanofi.com/investors . You should read the filings made by Sanofi and Ablynx with the SEC carefully before making a decision concerning the U.S. Offer .

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shareholder Votes Clear ODNB-NACB Merger's Final Hurdle

Updated Category News Views 24

A merger vote rarely makes anyone pound the table, but it does remove one very real way a bank deal can stumble. ODNB Financial Corporation and National Capital Bancorp, Inc. have announced that their shareholders approved the proposed merger. That is meaningful progress, plain and simple. It says the owners who get to live with the outcome have signed off on joining the...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 37

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Würk's Bryte AI Targets Payroll's Costly Friction Points

Updated Category News Views 83

Payroll mistakes are the sort of paper cuts that suddenly turn into a hospital bill for an employer. Würk’s Nov. 19 launch of Bryte AI goes straight at that ugly reality in cannabis, beverage alcohol, and other heavily regulated workplaces, where a bad time entry, missed document, or misunderstood policy can create a far more expensive mess than ordinary office...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 37

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
MedStar's Same-Day Test Puts Stroke Drugs on Notice

Updated Category News Views 25

A five-hour lab result can matter more than another glossy precision-medicine slogan. MedStar Health says it is using same-day genetic testing for patients with ischemic stroke, giving clinicians information before discharge that previously often arrived more than a week later. That is a practical change, not science-fiction wallpaper: a treatment decision gets made while...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 95

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 123

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Action1's 3,688% Growth Puts Patching on Investor Maps

Updated Category News Views 52

Patch Management Finally Gets Some Respect Nothing makes a security buyer flinch faster than a machine carrying a known vulnerability for weeks, and Action1 has plainly found that nerve. The Houston-based autonomous endpoint management company says it was the fastest-growing endpoint management vendor on Deloitte's 2026 Technology Fast 500 for the second consecutive year,...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 99

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading

Top 5 Most Recently Viewed Articles

A.O. Smith Sells 81% of China Arm to CPE: Key Takeaways

Updated Category News Views 372

When a major player like A.O. Smith decides to offload a piece of its business, folks tend to sit up and pay attention. This isn't just some run-of-the-mill shuffling. A.O. Smith has inked a deal with CPE to hand over an 81% stake in its China business. What does this transaction bring to the table and who stands to gain? Broken Down for the Curious Investor The numbers...

Continue Reading
NCCN Expands Global Influence at Historical Cancer Forum

Updated Category News Views 177

NCCN’s Involvement in Global Cancer Initiatives The National Comprehensive Cancer Network is actively participating in a progressive forum uniting various organizations dedicated to cancer control. This gathering includes representatives from approximately 75 nations, marking a significant milestone in international collaboration. Focus of the Cancer Planners Forum The...

Continue Reading
eGlint's Rapid Tech Revolutionizes Proteomics with Win

Updated Category News Views 85

A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...

Continue Reading
Exploring the Surge in Options Trading with GE Vernova Insights

Updated Category News Views 67

Understanding the Current Options Trading Landscape of GE Vernova Recently, financial sectors have shown strong bullish interest in GE Vernova. Our detailed analysis indicates a noteworthy trend in options trading for GE Vernova (GEV), where we've identified an impressive number of unusual trading activities. Digging deeper into the specifics, we observed that 66% of...

Continue Reading
Volatus Aerospace: Leading the Charge in Aerial Innovations

Updated Category News Views 310

Volatus Aerospace: Leading the Charge in Aerial Innovations Volatus Aerospace Inc. (TSXV: FLT, OTCQX: TAKOF, Frankfurt: ABB) continues to excel as a frontrunner in sovereign aerial solutions. The company recently shared an impressive corporate update, showcasing its robust financial standing, an increasing array of international contracts, and a commitment to align with...

Continue Reading